These results establish a new molecular imaging method to analyze CXCL12-CXCR4 signaling in ovarian cancer and suggest possible therapeutic benefit of combining selective inhibition of this chemokine receptor pathway with standard chemotherapeutic drugs. Here, CXCR4 is linked to ovarian cancer.